美国 · 平台与数据 · Morningstar

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

来源：Morningstar · 美国 15 小时前

Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced Phase 2 results for…

在 Morningstar 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

推荐阅读

American Express: 3 Key Takeaways for Long-Term Investors

Genmab A/S (NASDAQ:GMAB) Stock Price Up 7.4% - What's Next?

SLB surges on strong Q3 results, upbeat 2027 outlook as Middle East rebounds

‘Some people did everything right’: I lost my home in the Great Recession. I rent in my 50s. Why is that judged as failure?

Jana Small Finance Bank Q2 FY27 slides: record profit drives guidance upgrade

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

分享

推荐阅读

American Express: 3 Key Takeaways for Long-Term Investors

Genmab A/S (NASDAQ:GMAB) Stock Price Up 7.4% - What's Next?

SLB surges on strong Q3 results, upbeat 2027 outlook as Middle East rebounds

‘Some people did everything right’: I lost my home in the Great Recession. I rent in my 50s. Why is that judged as failure?

Jana Small Finance Bank Q2 FY27 slides: record profit drives guidance upgrade

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030